Cancer Control Journal Vol 4, No 1
CME Pretest

In this issue, the topic of endocrine malignancy is addressed. First, answer the pretest questions below. After reading the articles, proceed with answering the CME posttest questions.

This Journal provides 4 hours of Category I Continuing Medical Education

Complimentary CME Credits

Physicians can earn up to 4 credit hours of Category I for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions on the posttest at the end of this issue. Complete instructions are given on the posttest pages. Every successfully answered 10 questions will earn 1 credit hour. CME is presented by an unrestricted educational grant from Bristol-Myers Oncology Division.

Educational Objectives

After reading this issue, clinicians will be expected to:

• recognize the presentation, biologic behavior, and the treatment options for several rare endocrine tumors, including H&uumlrthle cell carcinoma, carcinoid tumors, medullary thyroid cancer, and gastrinoma;
  
• be familiar with ¹¹¹In-pentetreotide as an imaging technique for accurate localization and staging of neuroendocrine tumors of the gastrointestinal system; and
  
• understand the utility of managment guidelines for patients with melanoma.

This program was planned in accordance with ACCME Essentials.
Release Date: Februrary 1, 1997 Expiration Date: February 1, 1998

Pretest

1. Which serum marker is of value in follow-up of patients with H&uumlrthle cell carcinoma?

a. thyroglobulin

b. calcitonin

c. carcinoembryonic antigen

d. lactate dehydrogenase

2. A patient with an atypical foregut carcinoma is most likely to exhibit an increased serum level of:

a. 5-hydroxyindoleacetic acid (5-HIAA)

b. neurotensin

c. 5-hydroxytryptophan (5-HTP)

d. dopamine

3. Patients with melanomas less than 1 mm in thickness are treated with surgical resection using what diameter of skin margins?

a. 1 cm

b. 2 cm

c. 5 cm

d. other